These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 11365366)
1. New questions about therapy. Boston AIDS Writers Group. Surviv News (Atlanta Ga); 1998 May; ():19-20. PubMed ID: 11365366 [TBL] [Abstract][Full Text] [Related]
2. Molecular biological assessment methods and understanding the course of the HIV infection. Katzenstein TL APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050 [TBL] [Abstract][Full Text] [Related]
3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Van Vaerenbergh K Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503 [TBL] [Abstract][Full Text] [Related]
4. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)]. Panel de expertos de Gesida y Plan Nacional sobre el Sida Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124 [TBL] [Abstract][Full Text] [Related]
5. Viral resistance: how it may affect treatment options. Biehler GV Body Posit; 1998 Jun; 11(6):42-3. PubMed ID: 11365610 [TBL] [Abstract][Full Text] [Related]
6. HIV drug resistance and the other causes of treatment failure. Schouten JT STEP Perspect; 1997; 9(3):5-8. PubMed ID: 11364937 [TBL] [Abstract][Full Text] [Related]
7. Drug failure and HIV resistance create frustrating scenarios for clinicians. Murphy MJ Fac Notes (New Orleans La); 1998; 10(5):1-3. PubMed ID: 11365830 [TBL] [Abstract][Full Text] [Related]
13. Triple combinations: present and future. Lange JM J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S77-82. PubMed ID: 8595515 [TBL] [Abstract][Full Text] [Related]
14. HIV-1 drug resistance assays in clinical management. Martinez-Picado J; D'Aquila R AIDS Clin Care; 1998 Nov; 10(11):81-5, 87-8. PubMed ID: 11365861 [TBL] [Abstract][Full Text] [Related]
15. New optimism on controlling HIV infection. James JS AIDS Treat News; 1996 Jun; (no 249):1-3. PubMed ID: 11363596 [TBL] [Abstract][Full Text] [Related]
16. Making the switch--ideas for when therapy fails. Vazquez E Posit Aware; 1998; 9(3):47-8. PubMed ID: 11365488 [TBL] [Abstract][Full Text] [Related]
17. New ways to treat HIV. Treat Rev; 1996 Dec; (No 23):2-3. PubMed ID: 11364281 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic options or antiretroviral anarchy? Mascolini M J Int Assoc Physicians AIDS Care; 1999 Jan; 5(1):10-30. PubMed ID: 11366158 [TBL] [Abstract][Full Text] [Related]
19. Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment. Sanchez R; Portilla J; Gimeno A; Boix V; Llopis C; Sanchez-Paya J; Merino E; de la Sen ML; Muñoz C; Reus S; Plazas J J Infect; 2007 Feb; 54(2):159-66. PubMed ID: 16690132 [TBL] [Abstract][Full Text] [Related]
20. Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks. Paton NI; Aboulhab J HIV Med; 2005 Jan; 6(1):13-20. PubMed ID: 15670247 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]